SCHEMBL6302584

SCHEMBL6302584

CCOC(=O)c1c(C(C)=O)c2ccccc2n1Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 12/20 0.62
LMNA P02545 3/20 0.56
MAPT P10636 3/20 0.56
GAA P10253 2/20 0.56
HTT P42858 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
ALDH1A1 P00352 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
HPGD P15428 1/20 0.48
CYP2C19 P33261 1/20 0.48
PTGES O14684 1/20 0.48
ALOX5 P09917 1/20 0.48
F10 P00742 1/20 0.47
ABCB11 O95342 1/20 0.46
KDM4E B2RXH2 1/20 0.46
PKM P14618 1/20 0.46
NOD2 Q9HC29 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5213680 0.94 CCR2 (0.65) CCR2LMNAMAPTGAAHTT
SCHEMBL5214863 0.92 CCR2 (0.76) CCR2LMNAMAPTGAAHTT
SCHEMBL5220576 0.88 CCR2 (0.61) CCR2LMNAMAPTGAAHTT
SCHEMBL5214927 0.86 CCR2 (0.59) CCR2LMNAMAPTGAAHTT
SCHEMBL8688955 0.86 CCR2 (0.59) CCR2LMNAMAPTGAAHTT
SCHEMBL5216535 0.86 CCR2 (0.59) CCR2LMNAMAPTGAAHTT
SCHEMBL6307834 0.85 CCR2 (0.84) CCR2LMNAMAPTALDH1A1CYP1A2
SCHEMBL5213262 0.84 CCR2 (0.57) CCR2LMNAMAPTGAAHTT
SCHEMBL5216641 0.84 MEN1 (0.63) CCR2LMNAMAPTGAAHTT
SCHEMBL5219665 0.83 CCR2 (0.56) CCR2LMNAMAPTGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6953809-B2 Monocyte chemoattractant protein-1 inhibitor compounds ZENECA LIMITED (GB) 2005-10-11 US disclosed
US-20030119830-A1 Monocyte chemoattractant protein-1 inhibitor compounds ZENECA LIMITED 2003-06-26 US disclosed
US-6441004-B1 INDOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS ZENECA LIMITED (GB) 2002-08-27 US disclosed
EP-1003504-A2 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS AstraZeneca UK Limited (GB) 2000-05-31 EP disclosed
WO-1999007351-A2 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS ZENECA LIMITED (GB) 1999-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119830-A1 Monocyte chemoattractant protein-1 inhibitor compounds CCL2, CCL11, CCR1 CCR2 4/4885LMNA 3090/4885MAPT 2876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.